Citations

Clear

114 citation(s) found for "Weller, M".

A Novel Endocytic Mechanism of Epidermal Growth Factor Receptor Sequestration and Internalization
Orth, James D. , Krueger, Eugene W. , Weller, Shaun G. , McNiven, Mark A.

Mayo Clinic

Cancer Research | April 3, 2006 | Volume: 66 | Issue: 7 | Pages: 3603-3610

10.1158/0008-5472.can-05-2916 | PMID 16585185 Get It

Abstract Cells form transient, circular dorsal ruffles or “waves” in response to stimulation of receptor tyrosine kinases, including epidermal growth factor receptor (EGFR) or platelet-derived growth factor receptor. These dynamic structures progress inward on the dorsal surface and disappear, occurring concomitantly with a marked reorganization of F-actin. The cellular function of these structures is largely unknown. Here we show that EGF-induced waves selectively sequester and internalize ∼50% of ligand-bound EGFR from the cell surface. This process requires receptor phosphorylation, active phosphatidylinositol 3-kinase, and dynamin 2, although clathrin-coated pits or caveolae are not required. Epithelial and fibroblast cells stimulated with EGF sequestered EGFR rapidly into waves that subsequently generated numerous receptor-positive tubular-vesicular structures. Electron microscopy confirmed that waves formed along the dorsal membrane surface and extended numerous tubules into the cytoplasm. These findings characterize a structure that selectively sequesters large numbers of activated EGFR for their subsequent internalization, independent of traditional endocytic mechanisms such as clathrin pits or caveolae. (Cancer Res 2006; 66(7): 3603-10)
Chemotherapy With or Without Radiotherapy in Limited-Stage Diffuse Aggressive Non-Hodgkin's Lymphoma: Eastern Cooperative Oncology Group Study 1484
Horning, Sandra J., Weller, Edie, Kim, KyungMann, Earle, John D., Glick, John H., O’Connell, Michael J. , Habermann, Thomas M.

Mayo Clinic

Journal of Clinical Oncology | June 22, 2004 | Volume: 22 | Issue: 15 | Pages: 3032-3038

10.1200/jco.2004.06.088 | PMID 15210738 Get It

Purpose To compare low-dose (30 Gy) radiotherapy (RT) with observation (OBS) in limited-stage aggressive lymphoma patients achieving complete remission (CR) after chemotherapy, and to measure conversion from partial response (PR) to CR with high-dose (40 Gy) RT. Patients and Methods From 1984 to 1992, stage I (with risk factors) and II adults with diffuse aggressive lymphoma in CR after eight cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) were randomly assigned to 30 Gy involved-field RT or OBS. PR patients received 40 Gy RT. Results Among 172 CR patients, the 6-year disease-free survival (DFS) was 73% for low-dose RT versus 56% for OBS (two-sided P = .05). Failure-free survival (two-sided P = .06), and time to progression (two-sided P = .06) also favored RT. Intent-to-treat analyses yielded similar results. No survival differences were observed. Three RT versus 15 OBS patients relapsed in initial disease sites. At 6 years, failure-free survival was 63% in PR patients; conversion to CR did not significantly influence clinical outcome. Conclusion For patients in CR after CHOP, low-dose RT prolonged DFS and provided local control, but no survival benefit was observed. The majority of PR patients were event-free at 6 years despite residual radiographic abnormalities. Future efforts should be directed toward improved imaging and more effective systemic therapies.
Human muscle cells express a B7‐related molecule, B7‐H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies
Wiendl, Heinz , Mitsdoerffer, Meike , Schneider, Dagmar, Melms, Arthur, Weller, Michael , Chen, Lieping , Lochmüller, Hanns , Weller, Michael , Wiendl, Heinz

Mayo Clinic

The FASEB Journal | August 18, 2003 | Volume: 17 | Issue: 13 | Pages: 1-16

10.1096/fj.03-0039fje | PMID 12923066 Get It

B7‐H1 is a novel B7 family protein attributed to costimulatory and immune regulatory functions. Here we report that human myoblasts cultured from control subjects and patients with inflammatory myopathies as well as TE671 muscle rhabdomyosarcoma cells express high levels of B7‐H1 after stimulation with the inflammatory cytokine IFN‐γ. Coculture experiments of MHC class I/II‐positive myoblasts with CD4 and CD8 T cells in the presence of antigen demonstrated the functional consequences of muscle‐related B7‐H1 expression: production of inflammatory cytokines, IFN‐γ and IL‐2, by CD4 as well CD8 T cells was markedly enhanced in the presence of a neutralizing anti‐B7‐H1 antibody. This observation was paralleled by an augmented expression of the T cell activation markers CD25, ICOS, and CD69, thus showing B7‐H1‐mediated inhibition of T cell activation. Further, we investigated 23 muscle biopsy specimens from patients with polymyositis (PM), inclusion body myositis (IBM), dermatomyositis (DM), and nonmyopathic controls for B7‐H1 expression by immunohistochemistry: B7‐H1 was expressed in PM, IBM, and DM specimens but not in noninflammatory and nonmyopathic controls. Staining was predominantly localized to areas of strong inflammation and to muscle cells as well as mononuclear cells. These data highlight the immune regulatory properties of muscle cells and suggest that B7‐H1 expression represents an inhibitory mechanism induced upon inflammatory stimuli and aimed at protecting muscle fibers from immune aggression.
Cortactin Is a Component of Clathrin-Coated Pits and Participates in Receptor-Mediated Endocytosis
Cao, Hong , Orth, James D. , Chen, Jing , Weller, Shaun G. , Heuser, John E., McNiven, Mark A.

Mayo Clinic

Molecular and Cellular Biology | February 28, 2003 | Volume: 23 | Issue: 6 | Pages: 2162-2170

10.1128/mcb.23.6.2162-2170.2003 | PMID 12612086 Get It